All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-06-08T09:02:51.000Z

Laurie Sehn | ASCO 2018 | Polatuzumab vedotin, bendamustine and rituximab combination for R/R DLBCL

By Sara Valente
Featured
Laurie Sehn
Jun 8, 2018
Share:

Bookmark this article

ASCO Annual Meeting, 1-5 June 2018, Chicago, IL
Laurie Sehn
British Columbia Cancer, Vancouver, CA

Interview topic: Polatuzumab vedotin, bendamustine and rituximab combination for R/R DLBCL

Laurie Sehn | ASCO 2018 | Polatuzumab vedotin, bendamustine and rituximab combination for R/R DLBCL

More about...
Aggressive B-cell lymphomasASCO 2018BendamustineDiffuse large B-cell lymphomaFollicular lymphomaIndolent B-cell lymphomasPolatuzumab vedotinRituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
47 votes - 76 days left ...

Related articles

Add bookmark

Polatuzumab or pinatuzumab vedotin plus rituximab for R/R NHL: Results from the ROMULUS phase II trial

This multicenter, open-label, randomized phase II study compared the efficacy of polatuzumab vedotin plus rituximab (R-pola) to pinatuzumab vedotin...

Apr 12, 2019
Add bookmark

Polatuzumab or pinatuzumab vedotin plus rituximab for R/R NHL: Results from the ROMULUS phase II trial

This multicenter, open-label, randomized phase II study compared the efficacy of polatuzumab...

Apr 12, 2019
Add bookmark

ASCO 2018 | The Highlights 

Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual meeting, Chicago, June 1-5

Aug 1, 2018
Add bookmark

ASCO 2018 | The Highlights 

Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual...

Aug 1, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox